2019 Specialty Drug Pipeline Tops SPT Week in Review

5. Obesity-Related Cancer Burden Varies Widely Among US States

Study finds at least a 1.5-fold difference between states with lowest and highest proportions of cancers related to obesity. Read more.

4. Dasatinib Receives FDA Approval for Pediatric Ph+ Acute Lymphoblastic Leukemia

The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Read more.

3. That Drug Costs What?

New high-cost gene therapies are pushing health care providers to explore new methods to help the US health care system to fund specialty drugs. Read more.

2. FDA OKs Large-Scale Commercial Production of Andexxa

Andexxa [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for patients treated with rivaroxaban or apixaban, when anticoagulation reversal is needed. Read more.

1. 2019 Pipeline: Specialty Drug Approvals on the Horizon

Looking ahead, there are a plethora of promising new treatments for a range of specialty conditions in the 2019 drug pipeline. Read more.